Petefészekrák: vizsgálatok itt: Izrael
21 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
- Where
- Ashdod, Haifa, Holon, Jerusalem, Nahariya, Petah Tikva, Safed, Tel Aviv, Tel HaShomer
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
See details and how to joinNCT07546500 - 3. fázisTaking peopleTorvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
- Where
- Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Tel Aviv
- Életkor
- 18 év and over
- People
- 950 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00 - 3. fázisTaking peopleA Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
- Where
- Haifa, Tel Aviv
- Életkor
- 18 év and over
- People
- 802 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07776691 · EU 2025-524592-22-00 - 1/2. fázisTaking peopleA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan
- Életkor
- 18 év and over
- People
- 605 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00 - 3. fázisTaking peopleA Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
- Where
- Jerusalem, Tel Aviv
- Életkor
- 18 év and over
- People
- 646 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07743164 · EU 2025-525130-59-00 - 3. fázisTaking peopleStudy of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Where
- Haifa, Jerusalem, Kfar Saba, Petah Tikva, Tel Aviv, Tel HaShomer
- Életkor
- 18 év and over
- People
- 582 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Where
- Hadera, Haifa, Jerusalem, Kfar Saba, Ramat Gan
- Életkor
- 18 év and over
- People
- 770 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00 - 1. fázisTaking peopleA Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- Where
- Haifa, Jerusalem, Ramat Gan
- Életkor
- 18 év and over
- People
- 285 worldwide
- Run by
- AbbVie
See details and how to joinNCT07278336 · EU 2025-522209-40-00 - 3. fázisTaking peopleA Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Where
- Haifa, Holon, Ramat Gan
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00 - 1/2. fázisTaking peoplePhase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Where
- Haifa, Ramat Gan
- Életkor
- 18 év to 130 év
- People
- 622 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00 - 2. fázisTaking peopleA Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- Where
- Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 377 worldwide
- Run by
- AbbVie
See details and how to joinNCT07024784 - 1/2. fázisTaking peopleStudy of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Where
- Haifa, Jerusalem, Tel HaShomer
- Életkor
- 18 év and over
- People
- 890 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03564340 · EU 2024-510783-23-00 - 1/2. fázisTaking peopleA Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- Where
- Haifa, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 1109 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04895709 - 3. fázisTaking peopleAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Where
- Afula, Beersheba, Hadera, Haifa, Holon, Jerusalem, Kfar Saba, Nahariya, Ramat Gan, Sofia, Tel Aviv
- Életkor
- 18 év and over
- People
- 1100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07218809 · EU 2025-520466-22-00 - 2. fázisTaking peopleA Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
- Where
- Haifa
- Életkor
- 18 év and over
- People
- 37 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT04641247 · EU 2023-506618-29-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Beer Ya'akov, Haifa, Jerusalem, Kefar Sava, Petah Tikva, Ramat Gan, Tel Aviv
- Életkor
- 18 év and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - 1/2. fázisTaking peopleAutologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
- Where
- Jerusalem
- Életkor
- 18 év and over
- People
- 50
- Run by
- Hadassah Medical Organization
See details and how to joinNCT00722228 - 1/2. fázisTaking peopleAnti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
- Where
- Jerusalem
- Életkor
- 18 év to 70 év
- People
- 3
- Run by
- Hadassah Medical Organization
See details and how to joinNCT05296564 - 2. fázisTaking peopleInhibiting Beta-adrenergic and COX-2 Signaling During the Perioperative Period to Reduce Ovarian Cancer Progression
- Where
- Ramat Gan, Tel Aviv
- Életkor
- 20 év to 85 év
- People
- 60
- Run by
- Tel-Aviv Sourasky Medical Center
See details and how to joinNCT06839144 - 2. fázisTaking peoplePembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
- Where
- Ramat Gan
- Életkor
- 18 év and over
- People
- 24
- Run by
- Sheba Medical Center
See details and how to joinNCT04519151